Skip to main content

Table 2 Comparison of MSC and control group patient characteristics

From: Efficacy and safety of human umbilical cord-derived mesenchymal stem cells for COVID-19 pneumonia: a meta-analysis of randomized controlled trials

Patient characteristics

Total

MSC

Ctrl

Number of patients

328

169

159

Number of females

126

65

61

Mean age

61.25

61.33

61.1

Covid-19 severity

   

Mild/moderate

31

15

16

Severe

231

121

110

Critical

66

33

33

Comorbidities

   

Heart disease

30

18

12

Hypertension

103

47

56

Chronic respiratory disease

9

5

4

Smoker

2

0

2

Obesity

29

18

11

Diabetes

64

32

32

History of liver and kidney disease

12

4

8

Othersa

10

6

4

Total

259

130

129

Baseline therapy

   

Oxygen therapy

154

84

70

Non-invasive mechanical

30

18

12

Invasive mechanical

31

11

20

Corticosteroids

80

43

37

Antibiotic

76

45

31

Anti-virus therapy

98

54

44

Immunomodulatory drugs

10

4

6

On vasopressors

19

5

14

Total

498

264

234

  1. Othera include stroke, cerebrovascular disease, active neoplasia, immunodeficiency, cancer, tuberculosis